Quarterly ResultMay 13, 2026, 08:16 AM
Century Therapeutics Q1 Net Loss $21.6M; CNTY-813 IND on track for 4Q 2026
AI Summary
Century Therapeutics reported a net loss of $21.6 million for Q1 2026, a significant decrease from a net income of $76.6 million in Q1 2025, primarily due to no collaboration revenue this quarter. Despite the financial loss, the company highlighted strong pipeline execution, with its lead type 1 diabetes program, CNTY-813, on track for an IND submission in Q4 2026 and initial clinical data in H2 2027. Century also plans to advance CNTY-308 into clinical testing in 2026 and maintains a cash runway into Q1 2029, supported by a recent $135 million private placement.
Key Highlights
- Q1 2026 Net Loss: $(21.6) million, compared to $76.6 million net income in Q1 2025.
- Q1 2026 Collaboration Revenue: $0, down from $109.164 million in Q1 2025.
- Cash, cash equivalents, and marketable securities: $217.0 million as of March 31, 2026.
- Cash runway: Projected into Q1 2029.
- CNTY-813 (type 1 diabetes): IND submission on track for Q4 2026; clinical data expected H2 2027.
- CNTY-308 (CAR-iT cell therapy): On track to advance into clinic in 2026.
- Q1 2026 R&D Expenses: $17.1 million, a decrease from $26.6 million in Q1 2025.
Price Impact
More from IPSC